TOWARD PERSONALIZED MEDICINE IN THE NEUROPSYCHIATRIC FIELD

被引：12

作者：

Wong, Erik H. F. ^{[1
]}

Fox, Jayne C. ^{[2
]}

Ng, Mandy Y. M. ^{[2
]}

Lee, Chi-Ming ^{[3
]}

机构：

[1] AstraZeneca, External Sci, CNS Pain Innovat Med Unit, Wilmington, DC USA

[2] AstraZeneca, Personalized Hlth Care & Biomarkers, Macclesfield, Cheshire, England

[3] AstraZeneca, Discovery Enabling Capabil & Sci, Macclesfield, Cheshire, England

来源：

BIOMARKERS OF NEUROLOGICAL AND PSYCHIATRIC DISEASE | 2011年 / 101卷

关键词：

STAR-ASTERISK-D; GENOME-WIDE ASSOCIATION; ALZHEIMERS-DISEASE; MAJOR DEPRESSION; INTERMEDIATE PHENOTYPES; MELANCHOLIC FEATURES; MISMATCH NEGATIVITY; MISSENSE MUTATIONS; TREATMENT RESPONSE; DRUG DISCOVERY;

D O I：

10.1016/B978-0-12-387718-5.00013-4

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

There are great expectations for the personalized medicine approach to address the therapeutic needs of patients in the twenty-first century Advances in human genome science and molecular innovations in neuroscience have encouraged the pharmaceutical industry to focus beyond broad spectrum population therapeutics-the driving force behind the "blockbuster" product concept-to personalized medicine. For central nervous system (CNS) therapeutics, repeated failures in converting scientific discoveries to clinical trial successes and regulatory approvals have precipitated a drug pipeline crisis and eroded confidence in the industry This chapter describes how innovations in genomics and translational medicine can impact the future of neuropsychiatry and deconvolute the complexity of psychiatric diseases from symptoms biology A targeted and consistent investment is needed to restore confidence in translating science into clinical success.

引用

页码：329 / 349

页数：21

共 50 条

[21] Biomarker development for sarcoma toward personalized medicine
Kondo, Tadashi
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S132 - S132
[22] The biomarker revolution: a step toward personalized medicine
Bonnefoy, Jean-Yves
PERSONALIZED MEDICINE, 2008, 5 (06) : 553 - 556
[23] Moving Toward Personalized Medicine in Gynecologic Cancers
Ludwig, Michelle
Taunk, Neil
Chino, Junzo
Hathout, Lara
Leung, Eric
Fields, Emma
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 119 (01): : 1 - 5
[24] 'Generic to genetic' transition in cardiovascular and neuropsychiatric drugs: opportunity for personalized medicine
Duconge, Jorge
Ruano, Gualberto
PHARMACOGENOMICS, 2012, 13 (10) : 1097 - 1100
[25] Neurological Disease in Lupus: Toward a Personalized Medicine Approach
McGlasson, Sarah
Wiseman, Stewart
Wardlaw, Joanna
Dhaun, Neeraj
Hunt, David P. J.
FRONTIERS IN IMMUNOLOGY, 2018, 9
[26] Precision Medicine & Pharmacogenomics: Personalized Medication in Neuropsychiatric Disorders using AI and telepsychiatry
Gkouvas, N.
EUROPEAN PSYCHIATRY, 2022, 65 : S678 - S678
[27] Pharmacogenomics and antihypertensive drugs: a path toward personalized medicine
Marteau, Jean-Brice
Gambier, Nicolas
Jeannesson, Elise
Siest, Gerard
Visvikis-Siest, Sophie
PERSONALIZED MEDICINE, 2007, 4 (04) : 393 - 412
[28] Treatments of inflammatory bowel disease toward personalized medicine
Ki-Uk Kim
Jisu Kim
Wan-Hoon Kim
Hyeyoung Min
Chang Hwan Choi
Archives of Pharmacal Research, 2021, 44 : 293 - 309
[29] Toward personalized medicine in Bardet-Biedl syndrome
Kenny, Joanna
Forsythe, Elizabeth
Beales, Philip
Bacchelli, Chiara
PERSONALIZED MEDICINE, 2017, 14 (05) : 447 - 456
[30] Toward a Personalized Medicine in Wake-up Stroke?
Yulug, Burak
Hanoglu, Lutfu
Kilic, Ertugrul
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2017, 16 (10) : 1049 - 1049

← 1 2 3 4 5 →